Lynx1 Capital Management LP: STOKE THERAPEUTICS INC (STOK): Quarterly 13F Position History
As of Q1 2026, Lynx1 Capital Management LP reported 4,763,673 shares of STOKE THERAPEUTICS INC (STOK), worth $155.1M and representing 24.5% of its 13F equity book. Quarter-over-quarter share count change: 641,001 (-11.9%) . The position first appeared in Q3 2023 and has been disclosed across 11 13F-HR filings in Pactolio's tracked window.
- 4,763,673Shares Held (Latest Filing)
- $155.1MReported Market Value (Latest Filing)
- 24.5%Portfolio Weight (% of 13F Equity Book)
- 641,001Quarter-over-Quarter Share Change
- -$16.4MQuarter-over-Quarter Value Change
- 5,404,674Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 11 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 4,763,673 | 641,001 | -11.9% | $155.1M | 24.5% | $32.6 |
| Q4 2025 | 5,404,674 | 0 | — | $171.5M | 34.7% | $31.7 |
| Q3 2025 | 5,404,674 | 0 | — | $109.9M | 22.4% | $20.3 |
| Q2 2025 | 5,404,674 | +112,745 | +2.1% | $61.3M | 17.7% | $11.3 |
| Q1 2025 | 5,291,929 | +104,738 | +2.0% | $35.2M | 12.6% | $6.7 |
| Q4 2024 | 5,187,191 | 0 | — | $57.2M | 21.5% | $11.0 |
| Q3 2024 | 5,187,191 | +2,000 | +0.0% | $63.8M | 22.6% | $12.3 |
| Q2 2024 | 5,185,191 | +1,488,371 | +40.3% | $70.1M | 25.4% | $13.5 |
| Q1 2024 | 3,696,820 | +739,902 | +25.0% | $49.9M | 12.9% | $13.5 |
| Q4 2023 | 2,956,918 | +1,246,764 | +72.9% | $15.6M | 6.1% | $5.3 |
| Q3 2023 | 1,710,154 | — | — | $6.7M | 4.5% | $3.9 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Lynx1 Capital Management LP first disclose a STOK position in 13F-HR filings?
Lynx1 Capital Management LP first reported STOKE THERAPEUTICS INC (STOK) on its 13F-HR filing for the period ending 2023-09-30 (Q3 2023). The position has appeared on 11 reported quarters within Pactolio's tracked window.
What was Lynx1 Capital Management LP's most recent quarter-over-quarter share-count change in STOK?
Between Q4 2025 and Q1 2026, Lynx1 Capital Management LP reduced its STOK position by 641,001 shares (-11.9%), leaving 4,763,673 shares at a market value of $155.1M.
Does the implied price-per-share represent Lynx1 Capital Management LP's cost basis in STOK?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.